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O .S. N ielsen is Head of the D epartm ent of Oncology, Aarhus University Hospital, D enm ark. T he departm ent is responsible for radiation and m edical oncology and m edical physics, as well as experim ental clinical oncology. He becam e a D octor of M edical Science at Aarhus U niversity H ospital in 1984. H e has had a distinguished career in oncology, becom ing Associate Professor in Oncology at the Aarhus University Hospital in 1995, where he is involved in pre-and postgraduate teaching. H e has participated in the organisation of several international m eetings and courses within the ® elds of hyp ertherm ic oncology, radiation oncology, palliative m edicine, bone m etastases and sarcom as. H e has been C hairm an of a num ber of international m eetings, as w ell as being a m em ber of several national and international cancer societies. He was the previous Chairm an of the D anish Society of Oncology, and is the present Secretary of the EO RTC Soft Tissue and Bone Sarcoma Group. As well as being involved in the review of several international cancer journals, he has co-authored around 100 publications and m ade around 150 presentations at international m eetings. C urrently, his m edical and clinical activities cover the treatm ent of anal, oesophageal and gynaecological cancers, as w ell as soft tissue and bone sarcomas. In addition he is pursuing research activities in the area of palliative radiotherapy and quality of life. 
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Alan Craft is currently Professor of Child Health at the University of N ewcastle upon T yne. He established the N ewcastle Paediatric O ncology U nit in 1977 and was it' s D irector until 1992. He has a specialist clinical interest in the m anagement of bone tumours in children and young people, and for m any years was C hairm an of the U KCC SG Bone T um our C om m ittee and the MRC W orking Party on bone sarcoma. More recently he has been Chairm an of U KCC SG itself. H e w as a founder m ember of the European O steosarcom a Intergroup and is it' s current C hairm an. EO I has successfu lly completed two very large random ised trials w ith over 400 patients in each, the second one publish ed in The Lancet in 1997 showing an equivalence between a short 2-day regim e and a m ultidrug Rosen T 10 type of regim e. H e is also Co-chairm an of the European Intergroup Co-operative Ewing' s Sarcom a study, which is close to com pleting its ® rst large-scale multinational random ised trial.
